JPWO2022003421A5 - - Google Patents

Info

Publication number

JPWO2022003421A5

JPWO2022003421A5 JP2022580214A JP2022580214A JPWO2022003421A5 JP WO2022003421 A5 JPWO2022003421 A5 JP WO2022003421A5 JP 2022580214 A JP2022580214 A JP 2022580214A JP 2022580214 A JP2022580214 A JP 2022580214A JP WO2022003421 A5 JPWO2022003421 A5 JP WO2022003421A5

Authority

JP

Japan

Prior art keywords

milligrams

fixed dose

clofazimine

rifabutin

clarithromycin

Prior art date

2024-07-09

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000009472 formulation Methods 0.000 claims description 38
• 239000000203 mixture Substances 0.000 claims description 38
• 229940000425 combination drug Drugs 0.000 claims description 28
• WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 27
• 229960004287 clofazimine Drugs 0.000 claims description 27
• ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims description 25
• AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 25
• 229960002626 clarithromycin Drugs 0.000 claims description 25
• 229960000885 rifabutin Drugs 0.000 claims description 25
• 238000000034 method Methods 0.000 claims description 20
• 230000002685 pulmonary effect Effects 0.000 claims description 11
• 241000513886 Mycobacterium avium complex (MAC) Species 0.000 claims description 10
• 208000015181 infectious disease Diseases 0.000 claims description 8
• 241001502334 Mycobacterium avium complex bacterium Species 0.000 claims description 6
• 208000019693 Lung disease Diseases 0.000 claims description 5
• 239000002775 capsule Substances 0.000 claims description 4
• 201000010099 disease Diseases 0.000 claims description 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
• 239000002202 Polyethylene glycol Substances 0.000 claims description 2
• 239000012052 hydrophilic carrier Substances 0.000 claims description 2
• 239000012051 hydrophobic carrier Substances 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
• 229920001223 polyethylene glycol Polymers 0.000 claims description 2
• 239000002552 dosage form Substances 0.000 claims 6
• 239000003814 drug Substances 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1